Radiopharmaceutical supply disruptions and the use of 99mTc-hydroxymethylene diphosphonate as an alternative to 99mTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement

Miller, E. J., Campisi, R., Shah, N. R., McMahon, S., Cuddy, S., Gallegos-Kattan, C., Maurer, M. S., Damy, T., Slart, R. H. J. A., Bhatia, K., & Einstein, A. J. (2022). Radiopharmaceutical supply disruptions and the use of 99mTc-hydroxymethylene diphosphonate as an alternative to 99mTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement. Journal of Nuclear Cardiology, 29(5), 2748–2760. https://doi.org/10.1007/s12350-022-03059-5

Authors:

Edward J. Miller

Roxana Campisi

Nishant R. Shah

Sean McMahon

Sarah Cuddy

Cesia Gallegos-Kattan

Mathew S. Maurer

Thibaud Damy

Riemer H. J. A. Slart

Ketan Bhatia

Andrew J. Einstein